Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
People can wait years for donor transplants and this will cut waiting times significantly.
Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.
While new emerging technologies such as 3D Bio-Printing will one day let us print all kinds of human organs on demand, from beating hearts to kidneys, pancreases, and more, the technology isn’t quite ready yet. So, until that time arrives people who need organ transplants will be reliant on chimeric organs from animals like pigs, organs put in suspended animation, and traditional human organ transplants. But, with human organ transplants in short supply and needing to be a correct match for the recipients blood type some people can wait years for their transplants and others die before they get to the top of the lists.
Matching blood types from donor to recipient is one of the major problems in organ donation and it’s why so many people have to wait so long for organs. But now, a team of researchers in Canada has developed an enzyme treatment to convert donated organs to the universal O blood type, allowing them to be safely transplanted into any patient.
A person’s blood type is determined by the antigens on the surface of their red blood cells. Those with type A blood have the A antigen, type B has the B antigen, AB has both and O has neither. For blood transfusions or organ transplants, these types need to be matched to prevent dangerous immune responses like organ rejection, but that’s a messy process that sees many patients missing out.
Much research has gone into preventing organ rejection in recent years. Scientists have been experimenting with special coatings for blood vessels, drugs that increase protective T cells in organs, nanoparticles that “hide” the organ from the immune system, and protein baths that strip out all the donor’s cells so they can be replaced with the recipient’s.
For the new study, researchers from a range of institutions across Canada tested an experimental enzyme treatment to remove antigens from donated organs, essentially converting them into the universal type O. Two enzymes from the human gut, known as FpGalNAc deacetylase and FpGalactosaminidase, have previously been shown to convert type A blood cells to type O, so the team tested if they would also work for organs.
They did so using the Ex Vivo Lung Perfusion (EVLP) system, which is already used to improve organs for transplant by warming them up and pumping nutrients through them. In this case, that included these particular enzymes.
The team experimented on human lungs from type A donors which had already been deemed unsuitable for transplant, so they weren’t taking them away from potential recipients. Pairs of lungs were run through the EVLP system – one receiving the antigen-clearing enzymes and one going without. Then both lungs were tested with blood containing high levels of anti-A antibodies, simulating an incompatible transplant.
Sure enough, the enzyme treatment successfully removed over 97 percent of the A antigens in the organs. That resulted in the treated lungs faring much better when exposed to the blood, minimising immune injury while the control lungs showed signs of rejection.
The researchers say that this could be a major step towards making universal organs that can be transplanted into anybody who needs them.
“With the current matching system, wait times can be considerably longer for patients who need a transplant depending on their blood type,” said Dr. Marcelo Cypel, senior author of the study. “Having universal organs means we could eliminate the blood-matching barrier and prioritize patients by medical urgency, saving more lives and wasting less organs.”
The research was published in the journal Science Translational Medicine.
Source: University Health Network